iVAC-L-CLL01: Patient-individualized Peptide Vaccination in Combination With Lenalidomide After First Line Therapy of CLL
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 16 Nov 2016 Planned End Date changed from 1 Jun 2020 to 1 Oct 2020.
- 16 Nov 2016 Planned primary completion date changed from 1 Jun 2019 to 1 Oct 2019.
- 16 Nov 2016 Status changed from not yet recruiting to recruiting.